Therefore, we conducted a five-year prospective cohort study to confirm the prognostic value of AFP at baseline (b-AFP), subsequent AFP at relapse (r-AFP), and AFP alteration in virus-related HCC patients undergoing combination therapy. This evidence concerns the gene AFP and hepatocellular carcinoma.